Skip to main content
SpringerLink
Log in

Klinik und Therapie der Helicobacter-pylori-Infektion

  • Chapter
Infektiologie des Gastrointestinaltraktes

  • 1647 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W (1998) Primary and aquired Helicobacter pylori resistance to clarithromycin, metronidazole and amoxicillin. Am J Gastroenterol 93: 386–389

    PubMed  CAS  Google Scholar 

  • Adamsson I, Edlund C, Nord CE (2000) Microbial ecology and treatment of Helicobacter pylori infection: Rev J Chemother 12: 5–16

    CAS  Google Scholar 

  • Andersen IP, Colding H, Kristiansen JE (2000) Potentiation of the action of metronidazole on Helicobacter pylori by omeprazol and Bismuth subcitrate. Int J Antimicrob Agents 14: 231–234

    Article  PubMed  CAS  Google Scholar 

  • Bayerdörffer E, Hansky K, Schneider-Brachert W et al. (2002) Treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin — a prospective randomized trial comparing a 7-day rifabutin-based triple therapy with a high dose omeprazole/amoxiillin dual therapy. Gut 51(Suppl II): A91

    Google Scholar 

  • Bereswill S, Krainick C, Stahler F, Herrmann L, Kist M. (2003) Analysis of the rdxA gene in high-level metronidazole-resistant clinical isolates confirms a limited use of rdxA mutations as a marker for prediction of metronidazole resistance in Helicobacter pylori FEMS. Immunol Med Microbiol 36: 193–198

    Article  CAS  Google Scholar 

  • Best LM, Haldane DJ, Keelan M et al. (2003) Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother 47: 3138–3144

    Article  PubMed  CAS  Google Scholar 

  • Blandizzi C, Malizia T, Gherardi G et al. (1998) Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis. J. Antimicrob Chemother 42: 75–82

    Article  PubMed  CAS  Google Scholar 

  • Calabrese C, Di Febo G, Areni A, Scialpi C, Biasco G, Miglioli M (2000) Pantoprazole, azithromycin and tinidazole: short duration tripletherapy for eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 14: 1613–1617

    Article  PubMed  CAS  Google Scholar 

  • Cammarota G, Papa A, Cianci R et al. (1999) Three-day antibiotic therapy with azithromycin and tinidazole plus lanzoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study. Eur J Gastroenterol Hepatol 11: 247–250

    PubMed  CAS  Google Scholar 

  • Caspary WF, Arnold R, Bayerdörffer E et al. (1996) Diagnostik und Therapie der Helicobacter pylori Infektion. Leitlinien der DGVS. Z Gastroenterologie 34: 392–401

    CAS  Google Scholar 

  • Cooreman MP, Krausgrill P, Hengels KJ (1993) Local gastric and serum Amoxicillin concentrations after different oral application forms. Antimicrob Agents Chemother 37: 1506–1509

    PubMed  CAS  Google Scholar 

  • de Boer WA (1999) Bismuth triple therapy is still a very important drug regime for curing Helicobacter pylori infection. Eur J Gastroenterol Hepatolol 11: 697–700

    Google Scholar 

  • DeCross AJ, Marshall BJ, McCallum RW et al. (1993) Susceptibility testing for Helicobacter pylori: comparison of disk, broth, and agar dilution methods and their clinical relevance. J Clin Microbiol 31: 1971–1974

    PubMed  CAS  Google Scholar 

  • De Martel C, Llosa AE, Farr SF et al. (2005) Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. J Infect Dis 191: 761–767

    Article  PubMed  Google Scholar 

  • Dooley CP, Cohen H, Fitzgibbons P et al. (1989) Prevalence of Helicobacter pylori and histologic gastritis in asymptomatic persons. N Engl J Med 321: 1562–1566

    Article  PubMed  CAS  Google Scholar 

  • Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY (2000) Effect of pretreatment antibiotic resistance to Metronidazole and Clarithromycin on outcome of Helicobacter pylori therapy: A Meta-Analytical approach. Dig Dis Sci 45: 68–76

    Article  PubMed  CAS  Google Scholar 

  • Dore MP, Piana A, Carta M et al. (1998) Amoxicillin resistance is one reason for failure of Amoxicillin-Omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 12: 635–639

    Article  PubMed  CAS  Google Scholar 

  • Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC (1995) Effect of pH on the stability of Amoxicillin in buffered aqueous solution and in gastric juice. Pharm Sci 1: 597–600

    CAS  Google Scholar 

  • Ferrero M., Ducons JA, Santolaria B, Sierra E, Gomollon F (2000). Factors affecting the variation in antibiotic resistance of Helicobacter pylori. Int J Antimicrob Agents 16: 245–248.

    Article  PubMed  CAS  Google Scholar 

  • Fischbach W (2005) Tumore des Magens. In: Caspary WF, Mössner J, Stein J (Hrsg) Therapie gastroenterologischer Krankheiten. Springer, Heidelberg Berlin New York, S 90–97

    Google Scholar 

  • Fraser AG, Moore L, Hackett M, Hollis B (1999). Helicobacter pylori treatment and antibiotic susceptibility: Result of a fife-year Audit. Aust N Z J Med 29: 512–516

    PubMed  CAS  Google Scholar 

  • Furuta T, Ohashi K, Kamata T et al. (1998) Effect of genetic differences in omeprazole metabolism on cure rate of Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129: 1027–1030

    PubMed  CAS  Google Scholar 

  • Gerloff J, Mignot A, Barth H et al. (1996) Pharmacokinetics and absolute bioavailability of Lanzoprazole. Eur J Clin Pharmacol 50: 293–297

    Article  PubMed  CAS  Google Scholar 

  • Gisbert JP, Boixeda D, Bermojo F et al. (1999) Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 11: 1049–1054

    Article  PubMed  CAS  Google Scholar 

  • Gisbert JP, Calet X, Bujanda I, Marcos S, Gisbert JL, Pajares JM (2003) ‘Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 88: 90–94

    Article  Google Scholar 

  • Goddard AF (1998) Review Article: Factors influencing antibiotic transfer across the gastric mucosa. Aliment Pharmacol Ther 12: 1175–1184

    Article  PubMed  CAS  Google Scholar 

  • Goddard AF, Jessa MJ, Barrett DA et al. (1996). Effect of Omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 111: 358–367

    Article  PubMed  CAS  Google Scholar 

  • Greenberg RE, Bank S (1990) The prevalence of Helicobacter pylori in nonulcer dyspepsia. Arch Intern Med 150: 2053–2055

    Article  PubMed  CAS  Google Scholar 

  • Gschossmann JM, Haag S, Holtmann G (2001) Epidemiological trends of functional gastrointestinal disorders. Dig Dis 19: 189–194

    Article  PubMed  CAS  Google Scholar 

  • Harrison JD, Jones JA, Morris DL (1991) Azithromycin levels in plasma and gastric tissue, juice and mucus. Eur J Clin Microbiol Infect Dis 10: 862–864

    Article  PubMed  CAS  Google Scholar 

  • Heep M, Beck D, Bayerdörffer E, Lehn N (1999) Rifampin and Rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 43: 1497–1499

    PubMed  CAS  Google Scholar 

  • Helicobacter and Cancer Collaborative Group (2001) Gastric cancer and Helicobacter: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49: 247–353

    Article  Google Scholar 

  • Hirschl AM, Hirschl MM, Rotter ML (1993) Comparison of three methods for the determination of the sensitivity of Helicobacter pylori to metronidazole. J Antimicrob Chemother 32: 45–49

    PubMed  CAS  Google Scholar 

  • Holtmann G, Goebell H, Holtmann M, Talley NJ (1994) Dyspepsia in healthy blood donors: Pattern of symptoms and association with Helicobacter pylori. Dig Dis Sci 39: 1090–1098

    Article  PubMed  CAS  Google Scholar 

  • Horn J (2000) The proton-pump inhibitors: Similarities und differences. Clin Ther 22: 266–280

    Article  PubMed  CAS  Google Scholar 

  • Houben MHMG, van de Beek D, Hensen EF, De Craen AKM, Rauws EAJ (1999) A systematic review of Helicobacter pylori eradication therapy — The impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 13: 1047–1055

    Article  PubMed  CAS  Google Scholar 

  • Huang JQ, Sridhar S, Chen Y, Hunt RH (1998) Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114: 1169–1179

    Article  PubMed  CAS  Google Scholar 

  • Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH (2003) Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 125: 1636–1644

    Article  PubMed  Google Scholar 

  • Huber R, Hartmann M, Biesath H et al. (1996) Pharmacokinetics of Pantoprazole in man. Int J Pharmacol Ther 34(Suppl 1): S31–S50

    Google Scholar 

  • Jeong J-Y, Mukhopadhyay AK, Dailidiene D et al. (2000) Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high-level Metronidazole resistance in Helicobacter pylori. J Bacteriology 18: 5082–5090

    Article  Google Scholar 

  • Jungnickel PW (2000) Pantoprazole: A new proton-pump inhibitor. Clin Ther 22: 1268–1293

    Article  PubMed  CAS  Google Scholar 

  • Kalach N, Bergeret M, Benhamou PH, Dupont C, Raymond J (2001) High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol 39: 394–397

    Article  PubMed  CAS  Google Scholar 

  • Kist M, Berreswill S (1997) Helicobacter pylori. Teil 2: Epidemiologie, Diagnose und Therapie. Mikrobiologe 7: 209–211

    Google Scholar 

  • Klotz U (2000) Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 38: 243–270

    Article  PubMed  CAS  Google Scholar 

  • Labenz J, Börsch G (2000) Therapie der Helicobacter pylori Infektion. In: Malfertheiner P (Hrsg) Helicobacter pylori — Von der Grundlage zur Therapie. Thieme, Stuttgart, S 157–172

    Google Scholar 

  • Laine L, Schoenfeld P, Fennerty MB (2001) Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 134(5): 361–369

    PubMed  CAS  Google Scholar 

  • Lind T, Mégraud F, Unge P et al. (1999) The MACH 2 Study: Role of Omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116: 248–253

    Article  PubMed  CAS  Google Scholar 

  • Lind T, Veldhuyzen S, Unge P et al. (1996) Eradication of Helicobacter pylori using one-week tripple therapy combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1: 138–144

    PubMed  CAS  Google Scholar 

  • Lozniewski A, de Korwin JD, Muhale F, Jehl F (1998) Gastric diffusion of antibiotics used against Helicobacter pylori. Int J Antimicrob Agents 9: 181–193

    Article  CAS  Google Scholar 

  • Malfertheiner P, Holtmann G, Peitz U et al. (2001) Leitlinien der Deutschen Gesellschaft für Verdauungs-und Stoffwechselerkrankungen zur Behandlung der Dyspepsie. Z Gastroenterol 39(11): 937

    Article  PubMed  CAS  Google Scholar 

  • Malfertheiner P, Mégraud F, O’Morain C et al. (2002). Current concepts in the management of Helicobacter pylori infection — the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther 16: 167–180

    Article  PubMed  CAS  Google Scholar 

  • Manes G, Dominguez-Munoz JE, Uomo G et al. (1998) Increased risk for Helicobacter pylori recurrence by continuous acid suppression: a randomized controlled study. Ital J Gastroenterol Hepatol 30: 28–33

    PubMed  CAS  Google Scholar 

  • Mégraud F, Lehn N, Lind T et al. (1999) Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2-Study. Antimicrob Agents Chemother 43: 2747–2752

    PubMed  Google Scholar 

  • Mendz GL, Mégraud F (2002) Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol 10: 370–375

    Article  PubMed  CAS  Google Scholar 

  • Midolo P, Turnidge JD, Lambert JR (1997) Bactericidal activity and synergy studies of proton pump-inhibitors and antibiotics against Helicobacter pylori in vitro. J Antimicrob Chemother 39: 331–337

    Article  PubMed  CAS  Google Scholar 

  • Mirshahi F, Fowler G, Patel A, Shaw G (1998). Omeprazole may exert both a bacteriostatic and a bactericidal effect on the growth of Helicobacter pylori (NCTC11637) in vitro by inhibiting bacterial urease activity. J Clin Pathol 51: 220–224

    Article  PubMed  CAS  Google Scholar 

  • Ohkusa T, Fujiki K, Takashimizu I et al. (2001) Improvment in atrophic gastritis an intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 134: 380–386

    PubMed  CAS  Google Scholar 

  • Okada M, Nishimura H, Kawashima M et al. (1999) A new quadruple therapy for Helicobacter pylori: Influence of resistant strains on treatment outcome. Aliment Pharmacol Ther 13: 769–774

    Article  PubMed  CAS  Google Scholar 

  • Osato MS (2000) Antimicrobial susceptibility testing for Helicobacter pylori: Sensitivity test results and their clinical relevance. Curr Pharm Des 6: 1545–1555

    Article  PubMed  CAS  Google Scholar 

  • Osato MS, Reddy R, Reddy SG, Penland RL, Graham DY (2001). Comparison of the E-test and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 17: 39–44

    Article  PubMed  CAS  Google Scholar 

  • Perri F, Festa V, Clemente R et al. (2001) Randomized study of two »rescue« therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 95: 58–62

    Google Scholar 

  • Reinert RR, Al-Lahham A, Lemperle M et al. (2002) Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 49: 61–68

    Article  PubMed  CAS  Google Scholar 

  • Savarino V, Zentilin P, Bisso G et al. (2000) The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 14: 893–900

    Article  PubMed  CAS  Google Scholar 

  • Schreiber S, Nguyen TH, Stüben M, Scheid P (2000) Demostration of a pH gradient in the gastric gland of the acid-secreating Guinea Pig mucosa. Am J Gastrointest Liver Physiol 279: G597–G604

    CAS  Google Scholar 

  • Sharma P, Vakil N (2003) Helicobacter and reflux disease. Aliment Pharmacol Ther 17: 297–305

    Article  PubMed  CAS  Google Scholar 

  • Sjolund M, Wreiber K, Andersson DI et al. (2003) Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med 139: 483–487

    PubMed  Google Scholar 

  • Spencer CM, Faulds D (2000) Esoprazole. Drugs 60: 321–329

    Article  PubMed  CAS  Google Scholar 

  • Stedman CA, Barclay ML (2000) Review Article: Comparison of the pharmacocinetics, acid suppression and efficacy of proton-pump inhibitors. Aliment Pharmacol Ther 14: 963–978

    Article  PubMed  CAS  Google Scholar 

  • Stolte M (2000) Morphologie der Helicobacter pylori Gastritis. In: Malfertheiner P (Hrsg) Helicobacter pylori — Von der Grundlage zur Therapie. Thieme, Stuttgart, S 45–58

    Google Scholar 

  • Suerbaum S, Leying H, Klemm W, Opferkuch W (1991) Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. Eur J Clin Microbiol Infect is 10: 92–93

    Article  CAS  Google Scholar 

  • Talley NJ, Stanghellini V, Heading RC et al. (1999) Functional gastroduodenal disorders. Gut 45(Suppl. 2): 1137–1142

    Google Scholar 

  • Talley NJ, Holtmann G, Agreus L, Jones M (2000) Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: a four nations study. Am J Gastroenterol 95: 1439–1447

    Article  PubMed  CAS  Google Scholar 

  • Trautmann M, Riediger C, Moricke A, Vogt K, Bohr U, Glasbrenner B (1999) Combined activity of azithromycin and lansoprozole against Helicobacter pylori. Helicobacter 4: 113–120

    Article  PubMed  CAS  Google Scholar 

  • Trevisani L, Sartori S, Galvani F et al. (1998) Evaluation of a new ultrashort triple therapy of Helicobacter pylori disease. Aliment Pharmacol Ther 12: 1269–1272

    Article  PubMed  CAS  Google Scholar 

  • Uemura N, Okamoto S, Yamamoto S et al. (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789

    Article  PubMed  CAS  Google Scholar 

  • Uemura N, Okamoto S, Yamamoto S et al. (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789

    Article  PubMed  CAS  Google Scholar 

  • Vaira D, Vakil N, Rugge M et al. (2003) Effect of helicobacter eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut 52: 1543–1547

    Article  PubMed  CAS  Google Scholar 

  • Van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WD, Kleibeuker JH (1999) The influence of in vitro Nitroimidazole resistance on the efficacy of Nitroimidazole-containing anti-Helicobacter pylori regimes: A meta-analysis. Am J Gastroenterology 94: 1751–1759

    Article  Google Scholar 

  • Van der Wouden EJ, Thijs JC, van Zwet AA, Kleibeuker JH (2000) Review Article: Nitroimidazole resistance in Helicobacter pylori. Aliment Pharmacol Ther 14: 7–14

    Article  Google Scholar 

  • Van Oijen AHAM, Verbeek AL, Jansen JBMJ, De Boer WA (2000) Review Article: Treatment of Helicabacter pylori infection with Ranitidine, Bismuth Citrate-or proton pump inhibitor-based triple therapies. Aliment Pharmacol Ther 14: 991–999

    Article  PubMed  Google Scholar 

  • Van Zwet AA, Thijs JC, de Graaf B (1995) Explanations for high rates of eradication with the triple therapy using Metronidazole in patients harboring Metronidazole-resistent Helicobacter pylori strains. Antimicrob Agents Chemother 39: 250–252

    PubMed  Google Scholar 

  • Weiss K, Laverdière M, Restrieri C (1998) Comparison of activity of 10 antibiotics against clinical strains of Helicobacter pylori by three different techniques. Can J Gastroenterol 12: 181–185

    PubMed  CAS  Google Scholar 

  • Watanabe Y, Aoyama N, Shirasaka D et al. (2003) Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 35: 711–715

    Article  PubMed  CAS  Google Scholar 

  • Welage LS, Berardi RR (2000) Evaluation of Omeprazole, Lanzoprazole, Pantoprazole and Rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 40: 52–62

    CAS  Google Scholar 

  • Wong WM, Gu Q, Lam SK et al. (2003) Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 17: 553–560

    Article  PubMed  CAS  Google Scholar 

  • Zullo A, Hassan C, De F, V, Lorenzetti R et al. (2003) A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 35: 232–236

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Med. Mikrobiologie und Immunologie, Ruhr-Universität Bochum, Universitätsstraße 150, 44801, Bochum

    Prof. Dr. med. W. Opferkuch

  2. Abt. Mikrobiologie und Hygiene, Universitätsklinikum Freiburg, Hermann-Herder-Str. 11, 79104, Freiburg

    Prof. Dr. med. M. Kist

  3. Medizinische Klinik I, Klinikum der Johann Wolfgang, Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt am Main

    Prof. Dr. med. W. F. Caspary

Authors
  1. Prof. Dr. med. W. Opferkuch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. M. Kist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. W. F. Caspary
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentrum der Inneren Medizin, Medizinische Klinik I des Universitätsklinikums Frankfurt/Main, Theodor-Stern-Kai 7, 60590, Frankfurt/Main

    Wolfgang F. Caspary  & Jürgen Stein  & 

  2. Abteilung für Mikrobiologie und Hygiene, Universitätsklinikum Freiburg, Hermann-Herder-Str. 11, 79104, Freiburg

    Manfred Kist

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Opferkuch, W., Kist, M., Caspary, W.F. (2006). Klinik und Therapie der Helicobacter-pylori-Infektion. In: Caspary, W.F., Kist, M., Stein, J. (eds) Infektiologie des Gastrointestinaltraktes. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-37211-3_17

Download citation

  • DOI: https://doi.org/10.1007/3-540-37211-3_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41359-2

  • Online ISBN: 978-3-540-37211-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation